Gilead Sciences Inc. (GILD)

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2025 financial results and guidance will be released on Thursday, April 24...

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $105.25, denoting a +2% change from the preceding trading day.

Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

With equity markets in shambles due to President Donald Trump's trade policies, now might be as good a time as any to invest in excellent dividend stocks.

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and soli...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employe...

Healthcare stocks like GLID, COR, FMS and LMAT are a safe bet during times of market volatility.

The markets have succumbed to the tariff-fueled selling pressure, and there is nowhere to hide. President Trump’s tariff plan is intensifying the trade war. The Dow Jones Industrial is spiraling...

The Nasdaq 100 Index has slumped into a technical correction this year, falling by over 16% from its highest level in January. It has crashed to a low of $18,520, its lowest level since August 9 of la...